Ашық рұқсат
Рұқсат берілді
Рұқсат ақылы немесе тек жазылушылар үшін
№ 1 (2011)
- Жылы: 2011
- Мақалалар: 14
- URL: https://journals.eco-vector.com/2075-3594/issue/view/6298
Articles
4-7
8-14
15-22
23-29
ASSOCIATION OF LEPTINEMIA AND ADIPONECTINEMIA WITH CHRONIC KIDNEY DISEASE IN PATIENTS WITH METABOLIC SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE
Аннотация
Aim. Study of associations of leptinemia, adiponectinemia and progression of non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). Methods. 86 patients (64 male, 22 female; mean age 44+11 years) with metabolic syndrome, associated with NAFLD (ultrasound features of hepatic stetatosis and/or non-alcoholic steatohepatitis) were included into the study. Risk factors and plasma levels of leptin and adiponectin were determined.
Results. Patients with >3 signs of target organ damage (TOD) had the highest rate of non-alcoholic steatohepatitis (78% vs 39% in patients with 1 sign of TOD, р<0,05) and highest level of albuminuria (30,2 (17,3 - 48,0) vs 6,0 (4,3 - 9,0) mg/24 hours in group with 1 sign of TOD, p<0,05). Increase in number of signs of TOD was associated with elevation of leptin/adiponectin ratio. Group with NAFLD and CKD was characterized with elevation of elevation of fasting insulinemia, C-peptide level, HOMA-index and leptinemia. Leptinemia directly correlated with body mass index, systolic BP, fasting insulinemia, C-peptide level, HOMA-index and albuminuria. Plasma level of adiponectin inversely correlated with intima-media thickness of common carotid artery. Plasma adiponectin level directly correlated with HDL plasma level, leptinemia and DeRitis ratio
Conclusion. In metabolic syndrome NAFLD and CKD are associated; their progression is determined with adipokines disbalance and increase in insulin resistance.
Clinical nephrology. 2011;(1):30-34
30-34
VOZMOZhNOSTI SOVREMENNOY TERAPII KhRONIChESKOGO PIELONEFRITA V USLOVIYaKh DNEVNOGO STATsIONARA
Аннотация
Aim. Assessment of nadroparin calcium clinical efficacy in treatment of chronic pyelonephritis in day patient facility.
Methods. 31 patients with primary recurrent chronic pyelonephritis an 33 patients with secondary chronic pyelonephritis, associated with arterial hypertension, in day patient facility received nadroparin calcium (0,3 ml/day) for 10 days. 20 patients primary recurrent chronic pyelonephritis an 22 patients with secondary chronic pyelonephritis received placebo. Proteinuria, estimated glomerulary filtration rate (eGFR), creatinemia and renoscintigraphy parameters were evaluated. β2-microglobulin and N-acetyl- β-D-gexoamindase urinary excretion were determined and ambulatory blood pressure monitoring was performed.
Results. Nadroparin calcium therapy was associated with more pronounced decrease of proteinuria, leucocyturia, and blood pressure, especially in patients with secondary chronic pyelonephritis. Period of hospitalization also decreased.
Conclusion. Nadroparin calcium should be included into therapeutic strategies, which are used in chronic pyelonephritis
Clinical nephrology. 2011;(1):35-38
35-38
Influence of cardiovascular and renal risk factors on prognosis of coronary heart disease patients, undergone myocardial revascularization
Аннотация
Aim. Determination of role of kidney-related risk factors on cardiovascular survival in patients with coronary heart disease (CHD), undergone myocardial revascularization.
Methods. 90 patients with CHD, undergone myocardial revascularization, were included into the study. Cardiovascular and kidney-related risk factors were estimated; primary (acute myocardial infarction, recurrent myocardial revascularization, death) and surrogate (hospitalization and recurrent angina) endpoints were defined.
Results. 5 patients reached primary, 18 and 42 patients reached surrogate endpoints. Risk of primary endpoint was determined by triglyceride serum level and excess body weight. Risk of hospitalization was associated with elevation of triglyceride serum level, creatininemia and in smokers, risk of recurrent angina - with changes in creatininemia and glomerulary filtration rate, as well as chronic kidney disease, dyslipoproteidemia IIa and IIb and hypertriglyceridemia.
Conclusion. In patients with CHD, undergone myocardial revascularization, kidney-related risk factors influence the cardiovascular prognosis.
Clinical nephrology. 2011;(1):39-42
39-42
Сauses of death in patients receiving program heamodalysis
Аннотация
Aim. Assessment of causes of death in patients on program haemodialysis, based on demographic characteristics.
Methods. 88 patients on program haemodialysis, died from 2003 to 2010 years were analyzed.
Results. The leading cause of death was cardiovascular complications, but their role started to diminish since 2007. Women more oftener, than men, died from acute myocardial infarction and stroke. In younger age (16 - 45 years) main causes of death were chronic heart failure and stroke, but no acute myocardial infarctions were observed. In group age >45 years acute myocardial infarction was the third among leading causes of death (inferior to chronic heart failure and stroke.
Conclusion. Age and gender influence the structure of causes of death in patients on program haemodialysis.
Clinical nephrology. 2011;(1):43-45
43-45
EPIDEMIOLOGY AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC RENAL FAILIRE AND ANEMIA, RECEIVING PROGRAMM HEMODYALISISPart 1. Epidemiology and use of erythropoietin medications
Аннотация
Aim. Study of epidemiology and quality of life in patients with terminal renal failure and anemia, receiving program hemodyalisis.
Methods. Results of survey of 1395 patients with terminal renal failure and anemia, receiving program hemodyalisis, were analyzed.
Results. Mean age of patients were 42 years, 20% - >60 years. Main etiological causes of terminal renal failure were chronic glomerulonephritis and chronic pyelonephritis. 84% of patients had chronic kidney disease >2 years, 21,5% - >20 years. Majority of patients had concomitant diseases, 44,5% - visual disturbances. 72,7% had hemoglobin level > 100 g/l, 48,7% - >110 g/l; 26,8 - <100 g/l, 5,3% - < 80 g/l. 5% of patients during previous month received haemotransfusions. 83,5% received erythropoietin medications, predominantly Recormon and Eralfon. In 17 patients Eralfon was displaced by other erythropoietin medications; in 174 other erythropoietin medications were displaced by Eralfon .
Conclusion. Epidemiological characteristics of patients with terminal renal failure and anemia, receiving program hemodyalisis should lead to improvement of their management in routine clinical practice.
Clinical nephrology. 2011;(1):46-51
46-51
52-57
58-68
69-74
75-77
78-79